Lowering the <font color="red">triglyceride_1</font> <font color="red">/_1</font> <font color="red">high_1</font> <font color="red">-_1</font> <font color="red">density_1</font> <font color="red">lipoprotein_1</font> <font color="red">cholesterol_1</font> <font color="red">ratio_1</font> is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . 
<br>
<br> OBJECTIVES The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression . 
<br> BACKGROUND Diabetes mellitus is associated with accelerated coronary atheroma progression . Pioglitazone slowed progression compared with glimepiride in this population . 
<br> METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . <font color="red">Coronary_1</font> <font color="red">atheroma_1</font> <font color="red">progression_1</font> was evaluated by serial intravascular ultrasound . The relationship between <font color="red">changes_1</font> <font color="red">in_1</font> <font color="red">biochemical_1</font> <font color="red">parameters_1</font> <font color="red">,_1</font> <font color="red">percent_1</font> <font color="red">atheroma_1</font> <font color="red">volume_1</font> <font color="red">,_1</font> and <font color="red">total_1</font> <font color="red">atheroma_1</font> <font color="red">volume_1</font> was investigated . 
<br> RESULTS Pioglitazone - treated patients demonstrated greater increases in <font color="red">high_1</font> <font color="red">-_1</font> <font color="red">density_1</font> <font color="red">lipoprotein_1</font> <font color="red">cholesterol_1</font> <font color="red">(_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">)_1</font> and reductions in <font color="red">glycated_1</font> <font color="red">hemoglobin_1</font> <font color="red">,_1</font> <font color="red">triglycerides_1</font> <font color="red">,_1</font> and <font color="red">C_1</font> <font color="red">-_1</font> <font color="red">reactive_1</font> <font color="red">protein_1</font> <font color="red">._1</font> Significant correlations were observed between changes in percent <font color="red">atheroma_1</font> <font color="red">volume_1</font> and <font color="red">triglycerides_1</font> ( r = 0.15 , p = 0.04 ) , <font color="red">triglyceride_1</font> <font color="red">/_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">ratio_1</font> ( r = 0.16 , p = 0.03 ) , and <font color="red">glycated_1</font> <font color="red">hemoglobin_1</font> ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in <font color="red">low_1</font> <font color="red">-_1</font> <font color="red">density_1</font> <font color="red">lipoprotein_1</font> <font color="red">cholesterol_1</font> ( r = -0.15 , p = 0.05 ) , <font color="red">apolipoprotein_1</font> <font color="red">B_1</font> ( r = -0.16 , p = 0.04 ) , and <font color="red">apolipoprotein_1</font> <font color="red">A_1</font> <font color="red">-_1</font> <font color="red">I_1</font> ( r = -0.20 , p = 0.01 ) with glimepiride . Substantial atheroma regression , compared to progression , was associated with greater relative increases in <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> ( 14.2% vs. 7.8% , p = 0.04 ) , relative decreases in <font color="red">triglycerides_1</font> ( -13.3% vs. -1.9% , p = 0.045 ) , <font color="red">triglyceride_1</font> <font color="red">/_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">ratio_1</font> ( -22.5 vs. -9.9% , p = 0.05 ) , and decrease in <font color="red">glycated_1</font> <font color="red">hemoglobin_1</font> ( -0.6% vs. -0.3% , p = 0.01 ) . Multivariable analysis revealed that pioglitazone - induced effects on <font color="red">triglyceride_1</font> <font color="red">/_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> were associated with changes in percent <font color="red">atheroma_1</font> <font color="red">volume_1</font> ( p = 0.03 ) and <font color="red">total_1</font> <font color="red">atheroma_1</font> <font color="red">volume_1</font> ( p = 0.02 ) . 
<br> CONCLUSIONS Favorable effects of pioglitazone on the <font color="red">triglyceride_1</font> <font color="red">/_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">ratio_1</font> correlated with delayed <font color="red">atheroma_1</font> <font color="red">progression_1</font> in diabetic patients . This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease .